Vanda Pharmaceuticals (VNDA) Other financing activities (2010 - 2022)

Vanda Pharmaceuticals has reported Other financing activities for 10 years, with the latest figure at $571000.0 in Q4 2022.

• Quarterly Other financing activities fell 47.66% year-over-year to $571000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2023 was $575000.0 (down 17.86% YoY) and the FY2022 annual result came in at $700000.0, down 80.56% from the prior year.
• Other financing activities climbed to $571000.0 in Q4 2022 per VNDA's latest filing, from $4000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $3.6 million in Q2 2020 and troughed at $4000.0 in Q3 2022.
• A 5-year average of $1.2 million and a median of $571000.0 in 2022 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2018 and 2022: Other financing activities soared 481.54% in 2018, then sank 98.92% in 2022.
• Over 5 years, Other financing activities stood at $756000.0 in 2018, then jumped by 184.66% to $2.2 million in 2019, then plunged by 33.46% to $1.4 million in 2020, then fell by 23.81% to $1.1 million in 2021, then tumbled by 47.66% to $571000.0 in 2022.
• According to Business Quant data, Other financing activities over the past three periods registered $571000.0, $4000.0, and $125000.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.